Search Results
Jul 24, 2026, 09:10 ET A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Instinct Demo Showcase.The broader AI-drug-discovery field is drawing intense investor attention, with Recursion Pharmaceuticals (NASDAQ: RXRX), Absci (NASDAQ: ABSI), Tempus AI (NASDAQ: TEM), and NVIDIA (NASDAQ: NVDA) all central to how AI is reshaping the search for new medicines.A
More news about: American News Group
Jul 01, 2026, 09:00 ET As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
public life-sciences AI names, including Tempus AI (NASDAQ: TEM), AbCellera (NASDAQ: ABCL), Schrödinger (NASDAQ: SDGR), and Recursion (NASDAQ: RXRX), each distinct, and none a proxy for MindWalk.Patenting the Moat, Not the ModelThere is a growing consensus in artificial
More news about: USA News Group
Jun 30, 2026, 09:00 ET A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
AI-discovery approaches include Nkarta (NASDAQ: NKTX), Fate Therapeutics (NASDAQ: FATE), Compass Therapeutics (NASDAQ: CMPX), and Recursion (NASDAQ: RXRX), each distinct, and none a proxy for GT Biopharma.Putting AI to Work on the Hardest Part of Drug DesignThe core of the
More news about: USA News Group
Jun 16, 2026, 08:45 ET The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
the "design" layer of the field — complementary to the data-foundation layer MindWalk emphasizes.Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is among the largest and best-known "AI-first" drug discovery platforms, having industrialized the generation of biological data through massive
More news about: Equity Insider
Jan 29, 2026, 09:25 ET AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
Diagnostic Data Core is creating massive tailwinds for VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Recursion Pharmaceuticals (NASDAQ: RXRX), Tempus AI (NASDAQ: TEM), Schrodinger (NASDAQ: SDGR) and Eli Lilly (NYSE: LLY) as they bridge the gap between old-school hardware
More news about: Equity Insider
Dec 11, 2025, 10:17 ET Platform Technologies Drive $211B Surge in Precision Cancer Treatment
(NASDAQ: ERAS), Foghorn Therapeutics Inc. (NASDAQ: FHTX), OmniAb, Inc. (NASDAQ: OABI), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX).
More news about: Equity Insider